TargED Biopharmaceuticals
Entity

  • TargED Biopharmaceuticals

    Created in 2018


  • Up & running (A)
    Existing signals show a regular activity

  • Social networks

    4,239

  • Activities

    deeptech biotech

  • Entity types

    Startup

  • Location

    Vening Meinesz building C, Princetonlaan 6, 3584 CB Utrecht, Netherlands

    Utrecht

    Netherlands

  • Employees

    Scale: 11-50

    Estimated: 38

  • Engaged catalyst

    2
    0 0

  • Added in Motherbase

    8 months ago
Description
  • Value proposition

    Targeted Enzyme Delivery to improve thrombolysis

    TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.

    Biologicals, Thrombolysis, and Microvascular thrombosis

Catalyst interactions
Catalyst Type Tweets Articles
Eurazeo
Eurazeo
Finance, Financial Services (Auto)
Eurazeo
Finance, Financial Services (Auto) 		Other

31 May 2026


Kurma Partners
Kurma Partners
Startup accelerator & VC, Venture Capital and Private Equity Principals (Auto)
Kurma Partners
Startup accelerator & VC, Venture Capital and Private Equity Principals (Auto) 		Other

31 May 2026


Social network dynamics
Similar entities
BETA
Last news
Show all articles